StemCyte International, Ltd. (TPEX:4178)

Market Cap	5.06B
Revenue (ttm)	385.12M
Net Income (ttm)	-187.63M
Shares Out	192.24M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	145,143
Average Volume	339,275
Open	25.00
Previous Close	25.00
Day's Range	24.65 - 25.40
52-Week Range	20.50 - 55.70
Beta	n/a
RSI	62.62
Earnings Date	Nov 14, 2025

About StemCyte International

StemCyte International, Ltd. operates cord blood cell banks in the United States and Taiwan. It supplies cord blood to medical centers for transplantation in the treatment of blood system diseases; and provides cord blood supply, mononuclear cell supply, and immune cell supply services. The company also develops cord blood to treat COVID-19 syndrome and acute ischemic stroke; and CB201, an immune cell drug. In addition, it offers cord blood storage, immune cell storage, and cord blood cell bank transplant cell services. The company was founded ...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 2013
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4178

Financial Performance

In 2024, StemCyte International's revenue was 382.69 million, an increase of 5.49% compared to the previous year's 362.78 million. Losses were -205.66 million, -35.68% less than in 2023.